TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7669711

Group type: COMPARATOR
Intervention: 5-FU/FA (5-fluorouracil plus folinic acid)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 5-FU/FA/IFN (5-fluorouracil plus folinic acid plus interferon-alpha)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 5-FU/FA/IFN
Number of subjects: 149

Group type: COMPARATOR
Intervention: 5-FU/FA
Number of subjects: 149
Study: 2129490

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine b.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen b.d. + 20 mg famotidine b.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen b.d. + 40 mg famotidine nocte
Number of subjects: 18

Group type: COMPARATOR
Intervention: 500 mg naproxen b.d. + placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All treatment periods
Number of subjects: 18
Study: 6160364

Group type: EXPERIMENTAL
Intervention: Gamma Venin 10 g within the first 48 h after surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no Gamma Venin)
Number of subjects: 100
Study: 31842966

Group type: EXPERIMENTAL
Intervention: Small stitches closure followed by augmentation with a light-weight polypropylene mesh in the onlay technique
Number of subjects: 812

Group type: COMPARATOR
Intervention: Closure of the midline incision with a slowly absorbable monofilament suture in the small stitches technique
Number of subjects: 812
Study: 27486122

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (2 RDAs daily for 6 months)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (2 RDAs daily for 6 months)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Both vitamin B12 and folic acid supplementation (2 RDAs daily for 6 months)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Iron supplementation (daily for 2 months)
Number of subjects: 262
Study: 25920049

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24994725

Group type: EXPERIMENTAL
Intervention: FRAX treatment criteria
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bone density testing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Osteoporosis treatment
Number of subjects: 150
Study: 22611315

Group type: EXPERIMENTAL
Intervention: Small-volume epinephrine (15 to 25 mL injection; Group 1, n = 50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Large-volume epinephrine (30 to 40 mL injection; Group 2, n = 50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hemoclip (Group 3, n = 50)
Number of subjects: 150
Study: 19577967

Group type: EXPERIMENTAL
Intervention: Anterior route of conduit transposition
Number of subjects: 49

Group type: COMPARATOR
Intervention: Posterior route of conduit transposition
Number of subjects: 49
Study: 17541049

Group type: EXPERIMENTAL
Intervention: Duloxetine, 60 mg/day
Number of subjects: 311
Study: 15377554

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 1676
Study: 12187039

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 115

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 115
Study: 9846847

Group type: EXPERIMENTAL
Intervention: High oleate meal (95 g fat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fat meal (18 g MCT)
Number of subjects: 12
Study: 7865062

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (2 x ED 95)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.06 mg/kg rocuronium as priming dose followed by 0.24 mg/kg intubating dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (0.6 mg/kg and 0.06 mg/kg + 0.24 mg/kg)
Number of subjects: 30
Study: 2690557

Group type: EXPERIMENTAL
Intervention: Adjuvant single-agent doxorubicin
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: No or one risk factor
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Two risk factors
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Three or four risk factors
Number of subjects: 240
Study: 1060744

Group type: EXPERIMENTAL
Intervention: POMP alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PRAVD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: POMP-PRAVD
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: POMP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients less than 16 years
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients greater than 16 years
Number of subjects: 24
Study: 31561014

Group type: EXPERIMENTAL
Intervention: Pragmatic diagnostic accuracy studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explanatory diagnostic accuracy studies
Number of subjects: 0
Study: 30637662

Group type: EXPERIMENTAL
Intervention: 200 μg/day selenium supplements as selenium yeast (n=17)
Number of subjects: 33
Study: 29774682

Group type: EXPERIMENTAL
Intervention: Flupentixol/Melitracen 10.5 mg, QD, treatment lasts 4 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (specific immunotherapy only)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flupentixol/Melitracen combined with specific immunotherapy
Number of subjects: 99
Study: 25917673

Group type: EXPERIMENTAL
Intervention: bivalent OPV (bOPV) + inactivated polio vaccine (IPV)
Number of subjects: 928

Group type: COMPARATOR
Intervention: bivalent OPV (bOPV) only
Number of subjects: 928
Study: 23452344

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) using high-dose rocuronium, reversed by 4 mg/kg sugammadex
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (NMB) using a combination of atracurium and mivacurium, reversed by 1 mg neostigmine and 0.5 mg atropine
Number of subjects: 24
Study: 21239052

Group type: EXPERIMENTAL
Intervention: Community-based intervention package delivered by lady health workers (LHWs) including promotion of antenatal care, maternal health education, clean delivery kits, facility births, immediate newborn care, identification of danger signs, and promotion of care-seeking.
Number of subjects: 12391

Group type: EXPERIMENTAL
Intervention: Community-based intervention package delivered by lady health workers (LHWs).
Number of subjects: 12391

Group type: COMPARATOR
Intervention: Routine care provided in control clusters.
Number of subjects: 12391
Study: 19483447

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 50
Study: 17914039

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 15472765

Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Girdlestone situation (Control)
Number of subjects: 159
Study: 11510790

Group type: EXPERIMENTAL
Intervention: Conventional CPAP therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Auto CPAP therapy
Number of subjects: 33
Study: 9660042

Group type: EXPERIMENTAL
Intervention: Oral clonidine 4 microg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral diazepam 0.2 mg/kg
Number of subjects: 40
Study: 7646097

Group type: EXPERIMENTAL
Intervention: Completely heparin-coated circuit with reduced heparin dose (activated clotting time > 250 seconds)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group with uncoated circuit and full systemic heparinization (activated clotting time > 480 seconds)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 203
Study: 2785402

Group type: EXPERIMENTAL
Intervention: Sitting position using a newly designed obstetric chair
Number of subjects: 304

Group type: COMPARATOR
Intervention: Conventional dorsal position
Number of subjects: 304
Study: 23704

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 183

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 183
Study: 31809394

Group type: EXPERIMENTAL
Intervention: Autologous iliac bone graft
Number of subjects: 135

Group type: COMPARATOR
Intervention: Bioresorbable hydroxyapatite and calcium sulfate cement (CBVF)
Number of subjects: 135
Study: 31365402

Group type: EXPERIMENTAL
Intervention: Female MD
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Male MD
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Female NP
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Male NP
Number of subjects: 160
Study: 28599901

Group type: EXPERIMENTAL
Intervention: Intercurrent cardiovascular events (CV events)
Number of subjects: 4022

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 4022

Group type: COMPARATOR
Intervention: Myocardial infarction or stroke
Number of subjects: 4022

Group type: COMPARATOR
Intervention: Pre-ESRD events
Number of subjects: 4022

Group type: EXPERIMENTAL
Intervention: Post-ESRD mortality
Number of subjects: 4022
Study: 25484354

Group type: EXPERIMENTAL
Intervention: normobaric hypoxic bed rest (HBR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: normobaric hypoxic ambulatory confinement (HAMB)
Number of subjects: 11

Group type: COMPARATOR
Intervention: normobaric normoxic bed rest (NBR)
Number of subjects: 11
Study: 23459906

Group type: EXPERIMENTAL
Intervention: Moving Heart Program (intervention)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard-care control group
Number of subjects: 136
Study: 21164384

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 1150
Study: 19582982

Group type: EXPERIMENTAL
Intervention: Modified PHQ-12 item questionnaire
Number of subjects: 100

Group type: COMPARATOR
Intervention: PHQ-9 item questionnaire
Number of subjects: 100
Study: 16499978

Group type: EXPERIMENTAL
Intervention: Initial screening procedures for inclusion and exclusion criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selected women
Number of subjects: 0
Study: 15169793

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m²
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Paclitaxel 210 mg/m²
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m²
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Paclitaxel (all doses)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Paclitaxel (higher doses)
Number of subjects: 474
Study: 15176518

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study: 10671187

Group type: EXPERIMENTAL
Intervention: Physical training (3 times a week for 12 weeks)
Number of subjects: 29
Study: 9387047

Group type: EXPERIMENTAL
Intervention: Liposomally encapsulated daunorubicin (DaunoXome) at 120 mg/m2 repeated every 21 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Liposomally encapsulated daunorubicin (DaunoXome) at 40 mg/m2 repeated every 14 days
Number of subjects: 19
Study: 8404181

Group type: EXPERIMENTAL
Intervention: Salt loading (+ 6.1 +/‐ 2.8 g NaCl/d = + 105 +/‐ 48 mmol Na)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sodium citrate loading (+ 140 +/‐ 40 ml Shohl's solution, = + 120 +/‐ 30 mmol Na)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-salt diet (5 to 6 g NaCl/d = 86 to 103 mmol Na)
Number of subjects: 14
Study: 3528541

Group type: EXPERIMENTAL
Intervention: 250 mg disulfiram
Number of subjects: 605

Group type: COMPARATOR
Intervention: 1 mg disulfiram
Number of subjects: 605

Group type: COMPARATOR
Intervention: No disulfiram
Number of subjects: 605
Study: 2645950

Group type: EXPERIMENTAL
Intervention: Repeated treatment with daunorubicin (DNR), vincristine (VCR), and cytosine arabinoside (ara‐C)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Alternating treatment with amsacrine (AMSA) combined with high dose ara‐C and 5-azacytidine
Number of subjects: 515

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Overall survival for patients achieving CR
Number of subjects: 515

Group type: COMPARATOR
Intervention: Intensive combination of high-dose ara‐C and AMSA
Number of subjects: 515
Study: 31186180

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-assisted reconstruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoroscopy-free reconstruction
Number of subjects: 60
Study: 27337738

Group type: EXPERIMENTAL
Intervention: Neuro-exergaming (iPACES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exergaming alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neurogaming alone
Number of subjects: 30
Study: 25599904

Group type: EXPERIMENTAL
Intervention: HAPA-enhanced mindfulness training
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Basic mindfulness training
Number of subjects: 321

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 321
Study: 23404591

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 75
Study: 21054754

Group type: EXPERIMENTAL
Intervention: 200 mg of udenafil given 1 h before TURP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil given 1 h before TURP
Number of subjects: 30

Group type: COMPARATOR
Intervention: TURP without PDE5 Is
Number of subjects: 30
Study: 19145785

Group type: EXPERIMENTAL
Intervention: Integrated care based on teletransmitted home blood pressure (group B, n = 216)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Usual care based on office blood pressure (group A, n = 113)
Number of subjects: 329
Study: 17729044

Group type: EXPERIMENTAL
Intervention: Self-awareness training during IADLs (6 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapeutic practice during IADLs
Number of subjects: 20
Study: 15553286

Group type: EXPERIMENTAL
Intervention: Incremental technique with steel matrix bands
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Incremental technique with polyester matrix bands
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Prepolymerized resin particles with steel matrix bands
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Prepolymerized resin particles with polyester matrix bands
Number of subjects: 88
Study: 11465985

Group type: EXPERIMENTAL
Intervention: Systemic adenosine infusion (50 microg/kg/min for 60 min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Systemic adenosine infusion
Number of subjects: 26
Study: 9729704

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 54
Study: 8276659

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, 450 mg/m2 intravenously for 3 consecutive days during the first and last weeks of radiation therapy; Levamisole, 50 mg orally 3 times daily for 3 consecutive days concurrent with radiation therapy and 5-fluorouracil.
Number of subjects: 15
Study: 2606855

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NIC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 7
Study: 4844514

Group type: EXPERIMENTAL
Intervention: Quingestanol acetate (1.5 mg postcoital)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: d‐norgestrel (3.35 mg postcoital)
Number of subjects: 899
Study: 30649238

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (3 cycles of 5-min ischaemia/5-min reperfusion of the right arm using a blood pressure cuff inflated to 200 mmHg)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study: 25984590

Group type: EXPERIMENTAL
Intervention: Expert Streaming (ES)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Peer Consultation (PC)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fact Sheet Self-Study (FS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: All support programs (ES, PC, FS)
Number of subjects: 35
Study: 24888428

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (rt-PA) for anterior circulation strokes in patients with LVO
Number of subjects: 225

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (rt-PA) for anterior circulation strokes in patients with No-LVO
Number of subjects: 225
Study: 23271170

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21691117

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (20 mg/kg/day for 3 weeks)
Number of subjects: 40
Study: 19877264

Group type: EXPERIMENTAL
Intervention: TMG+
Number of subjects: 93

Group type: COMPARATOR
Intervention: TMG-
Number of subjects: 93
Study: 16952727

Group type: EXPERIMENTAL
Intervention: Intra-articular anesthesia
Number of subjects: 107

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 107
Study: 15499485

Group type: COMPARATOR
Intervention: Preventive Orientation (PO)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group of non-users in the last month (CONUM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group of users in the last month (COUM)
Number of subjects: 99
Study: 11561207

Group type: EXPERIMENTAL
Intervention: Prevention programme for allergy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group recommendations
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Detection of specific IgE against house-dust mite
Number of subjects: 43
Study: 9482363

Group type: EXPERIMENTAL
Intervention: Acetaminophen, aspirin, and caffeine combination
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study: 7923517

Group type: EXPERIMENTAL
Intervention: Vecuronium administered to patients with HPT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vecuronium administered to control patients
Number of subjects: 20
Study: 2894904

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg b.i.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31830868

Group type: EXPERIMENTAL
Intervention: arts therapies intervention
Number of subjects: 64
Study: 30925012

Group type: EXPERIMENTAL
Intervention: Educational film about body donors
Number of subjects: 77
Study: 27273298

Group type: EXPERIMENTAL
Intervention: Demineralized bovine bone mineral with 10% collagen (DBBM‐C) grafting
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no grafting)
Number of subjects: 86
Study: 26305528

Group type: EXPERIMENTAL
Intervention: First-eye cataract surgery
Number of subjects: 101

Group type: COMPARATOR
Intervention: Second-eye cataract patients
Number of subjects: 101

Group type: COMPARATOR
Intervention: Second-eye patients
Number of subjects: 101
Study: 24884624

Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single brain site involvement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single lesion
Number of subjects: 60
Study: 22920307

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (75 mg of clopidogrel in addition to 300 mg of aspirin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (300 mg of aspirin)
Number of subjects: 0
Study: 19702702

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) 0.05% ophthalmic emulsion twice daily and concomitant five times daily non-preserved artificial tear
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vehicle emulsion twice daily and non-preserved artificial tear five times daily (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA)
Number of subjects: 64
Study: 17688611

Group type: EXPERIMENTAL
Intervention: ISMN‐SR 60 mg vaginally
Number of subjects: 156

Group type: COMPARATOR
Intervention: Vitamin C 100 mg vaginally
Number of subjects: 156
Study: 15173774

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected MPI with ECG-gated data
Number of subjects: 90

Group type: COMPARATOR
Intervention: MPI alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: MPI plus ECG-gated data
Number of subjects: 90
Study: 11172267

Group type: EXPERIMENTAL
Intervention: Concave polyethylene insert (C, n = 25)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Posterior-stabilized polyethylene insert (PS, n = 22)
Number of subjects: 43
Study: 9556010

Group type: EXPERIMENTAL
Intervention: Human surfactant given at birth (prophylactic)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Human surfactant given after development of neonatal respiratory distress syndrome (rescue)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (air) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (children born at term)
Number of subjects: 40
Study: 7869468

Group type: EXPERIMENTAL
Intervention: Methadone alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Methadone plus 3 mg guanfacine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Methadone plus 4 mg guanfacine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (Methadone)
Number of subjects: 144
Study: 3122549

Group type: EXPERIMENTAL
Intervention: Active nitroglycerin patch
Number of subjects: 13

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 13
Study: 31154664

Group type: EXPERIMENTAL
Intervention: HDL-C increase
Number of subjects: 337
Study: 29770756

Group type: EXPERIMENTAL
Intervention: Whole blueberries
Number of subjects: 9

Group type: COMPARATOR
Intervention: Juiced blueberries
Number of subjects: 9
Study: 27718280

Group type: EXPERIMENTAL
Intervention: Cervical pessary plus 400 mg daily vaginal progesterone (group B)
Number of subjects: 144

Group type: COMPARATOR
Intervention: 400 mg daily vaginal progesterone (group A)
Number of subjects: 144
Study: 24933496

Group type: EXPERIMENTAL
Intervention: Brief telephone-based cognitive-behavioral therapy intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual services (Control)
Number of subjects: 300
Study: 22513062

Group type: EXPERIMENTAL
Intervention: Tramadol 2% plus adrenaline 1:200,000 (group T)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Lidocaine 2% plus adrenaline 1:200,000 (group L)
Number of subjects: 88